NOAEL Studies Cosmetic Ingredient

Maltitol NOAEL Studies

INCI: MALTITOL

CAS: 585-88-6

Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.

CIR Safety Assessment 16 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
CIR Safety Assessment NOAEL =69.09 % rat - - NOAEL study {"citation":"3; 20; 4","dose":"Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points.","effect":"in blood chemistry or urinalysis. Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points. Gross or histopathological changes were not observed. There was an increase in cecum diameter in males of the high-dose group, which the authors concluded to be due to higher values in 3 out of 20 rats; the opposite was observed for females of the low- and high-dose groups. In this study the no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day (Herrman 1993). Ocular and/or Mucosal Irritation Shiseido Research Center (2008a) studied the eye irritation of Maltitol (69.09%) in 3 rabbits. The test material was instilled into one eye of each animal without irrigation. The other eye remained untreated and served as the control. The eye reactions were evaluated according to the Draize scoring method. The eye","page":8,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"FR465_noael_001"}
CIR Safety Assessment NOAEL =2.5 g/kg/day New Zealand White rabbits (pregnant females) gavage day 6 through day 18 of pregnancy reproductive/developmental toxicity {"citation":"1","dose":"1.25, 2.5, or 5 g/kg/day","effect":"At 5 g/kg/day there was an increase in the number of early resorptions and increased post-implantation losses. No effects were observed in any treated group on maternal body weight increase, number of viable and dead fetuses, or on fetal body weights. No malformed fetuses were found at any of the doses administered.","page":6,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Bussi_1985_repro"}
CIR Safety Assessment NOAEL =69.09 % rat - - NOAEL study {"citation":"3; 20; 4","dose":"Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points.","effect":"in blood chemistry or urinalysis. Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points. Gross or histopathological changes were not observed. There was an increase in cecum diameter in males of the high-dose group, which the authors concluded to be due to higher values in 3 out of 20 rats; the opposite was observed for females of the low- and high-dose groups. In this study the no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day (Herrman 1993). Ocular and/or Mucosal Irritation Shiseido Research Center (2008a) studied the eye irritation of Maltitol (69.09%) in 3 rabbits. The test material was instilled into one eye of each animal without irrigation. The other eye remained untreated and served as the control. The eye reactions were evaluated according to the Draize scoring method. The eye","page":8,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"FR465_noael_001"}
CIR Safety Assessment NOAEL =2.5 g/kg/day New Zealand White rabbits (pregnant females) gavage day 6 through day 18 of pregnancy reproductive/developmental toxicity {"citation":"1","dose":"1.25, 2.5, or 5 g/kg/day","effect":"At 5 g/kg/day there was an increase in the number of early resorptions and increased post-implantation losses. No effects were observed in any treated group on maternal body weight increase, number of viable and dead fetuses, or on fetal body weights. No malformed fetuses were found at any of the doses administered.","page":6,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Bussi_1985_repro"}
CIR Safety Assessment NOAEL =69.09 % rat - - NOAEL study {"citation":"3; 20; 4","dose":"Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points.","effect":"in blood chemistry or urinalysis. Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points. Gross or histopathological changes were not observed. There was an increase in cecum diameter in males of the high-dose group, which the authors concluded to be due to higher values in 3 out of 20 rats; the opposite was observed for females of the low- and high-dose groups. In this study the no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day (Herrman 1993). Ocular and/or Mucosal Irritation Shiseido Research Center (2008a) studied the eye irritation of Maltitol (69.09%) in 3 rabbits. The test material was instilled into one eye of each animal without irrigation. The other eye remained untreated and served as the control. The eye reactions were evaluated according to the Draize scoring method. The eye","page":8,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"FR465_noael_001"}
CIR Safety Assessment NOAEL =2.5 g/kg/day New Zealand White rabbits (pregnant females) gavage day 6 through day 18 of pregnancy reproductive/developmental toxicity {"citation":"1","dose":"1.25, 2.5, or 5 g/kg/day","effect":"At 5 g/kg/day there was an increase in the number of early resorptions and increased post-implantation losses. No effects were observed in any treated group on maternal body weight increase, number of viable and dead fetuses, or on fetal body weights. No malformed fetuses were found at any of the doses administered.","page":6,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Bussi_1985_repro"}
CIR Safety Assessment NOAEL =69.09 % rat - - NOAEL study {"citation":"3; 20; 4","dose":"Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points.","effect":"in blood chemistry or urinalysis. Some differences were observed in hematological parameters; however, except for a decrease in leukocytes in the mid-dose females, none of these findings were present at all observation points. Gross or histopathological changes were not observed. There was an increase in cecum diameter in males of the high-dose group, which the authors concluded to be due to higher values in 3 out of 20 rats; the opposite was observed for females of the low- and high-dose groups. In this study the no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day (Herrman 1993). Ocular and/or Mucosal Irritation Shiseido Research Center (2008a) studied the eye irritation of Maltitol (69.09%) in 3 rabbits. The test material was instilled into one eye of each animal without irrigation. The other eye remained untreated and served as the control. The eye reactions were evaluated according to the Draize scoring method. The eye","page":8,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"FR465_noael_001"}
CIR Safety Assessment NOAEL =2.5 g/kg/day New Zealand White rabbits (pregnant females) gavage day 6 through day 18 of pregnancy reproductive/developmental toxicity {"citation":"1","dose":"1.25, 2.5, or 5 g/kg/day","effect":"At 5 g/kg/day there was an increase in the number of early resorptions and increased post-implantation losses. No effects were observed in any treated group on maternal body weight increase, number of viable and dead fetuses, or on fetal body weights. No malformed fetuses were found at any of the doses administered.","page":6,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Bussi_1985_repro"}
CIR Safety Assessment NOAEL =4.5 g/kg bw/day Crl:CD(SD)BR rats oral (diet) 52 weeks (chronic toxicity) / 106 weeks (carcinogenicity) chronic toxicity/carcinogenicity {"citation":"1","dose":"0, 0.5, 1.5, or 4.5 g/kg bw/day","effect":"no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Herrman_1993_chronic"}
CIR Safety Assessment NOAEL =4.5 g/kg bw/day Crl:CD(SD)BR rats oral (diet) 52 weeks (chronic toxicity) / 106 weeks (carcinogenicity) chronic toxicity/carcinogenicity {"citation":"1","dose":"0, 0.5, 1.5, or 4.5 g/kg bw/day","effect":"no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Herrman_1993_chronic"}
CIR Safety Assessment NOAEL =4.5 g/kg bw/day Crl:CD(SD)BR rats oral (diet) 52 weeks (chronic toxicity) / 106 weeks (carcinogenicity) chronic toxicity/carcinogenicity {"citation":"1","dose":"0, 0.5, 1.5, or 4.5 g/kg bw/day","effect":"no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Herrman_1993_chronic"}
CIR Safety Assessment NOAEL =4.5 g/kg bw/day Crl:CD(SD)BR rats oral (diet) 52 weeks (chronic toxicity) / 106 weeks (carcinogenicity) chronic toxicity/carcinogenicity {"citation":"1","dose":"0, 0.5, 1.5, or 4.5 g/kg bw/day","effect":"no adverse effect level (NOEL) was the highest dose tested - 4.5 g commercial product/kg bw/day","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"Herrman_1993_chronic"}
CIR Safety Assessment NOAEL =18 g/kg (rats); 43 g/kg (dogs) rats and dogs oral (diet) 90 days subchronic toxicity {"citation":"1","dose":"up to 18 g/kg (rats) and 43 g/kg (dogs) of body weight per day","effect":"no treatment-related toxicity was seen in any rats or dogs","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"WHO_1999_subchronic"}
CIR Safety Assessment NOAEL =18 g/kg (rats); 43 g/kg (dogs) rats and dogs oral (diet) 90 days subchronic toxicity {"citation":"1","dose":"up to 18 g/kg (rats) and 43 g/kg (dogs) of body weight per day","effect":"no treatment-related toxicity was seen in any rats or dogs","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"WHO_1999_subchronic"}
CIR Safety Assessment NOAEL =18 g/kg (rats); 43 g/kg (dogs) rats and dogs oral (diet) 90 days subchronic toxicity {"citation":"1","dose":"up to 18 g/kg (rats) and 43 g/kg (dogs) of body weight per day","effect":"no treatment-related toxicity was seen in any rats or dogs","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"WHO_1999_subchronic"}
CIR Safety Assessment NOAEL =18 g/kg (rats); 43 g/kg (dogs) rats and dogs oral (diet) 90 days subchronic toxicity {"citation":"1","dose":"up to 18 g/kg (rats) and 43 g/kg (dogs) of body weight per day","effect":"no treatment-related toxicity was seen in any rats or dogs","page":5,"pdf":"FR465.pdf","row_type":"noael_study","study_id":"WHO_1999_subchronic"}
EFSA 4 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
EFSA NOAEL =7600 mg/kg bw/day Rat oral: feed 91 days subchronic EFSA ANS - 2009 - OutputID 401 - no adverse effect observed at single/highest dose - Scientific Opinion on the use of Polyglycitol Syrup as a food additive - doi:10.2903/j.efsa.2009.1413
EFSA NOAEL =7600 mg/kg bw/day Rat oral: feed 91 days subchronic EFSA ANS - 2009 - OutputID 401 - no adverse effect observed at single/highest dose - Scientific Opinion on the use of Polyglycitol Syrup as a food additive - doi:10.2903/j.efsa.2009.1413
EFSA NOAEL =15400 mg/kg bw/day Rat oral: feed 91 days subchronic EFSA ANS - 2009 - OutputID 401 - no adverse effect observed at single/highest dose - Scientific Opinion on the use of Polyglycitol Syrup as a food additive - doi:10.2903/j.efsa.2009.1413
EFSA NOAEL =15400 mg/kg bw/day Rat oral: feed 91 days subchronic EFSA ANS - 2009 - OutputID 401 - no adverse effect observed at single/highest dose - Scientific Opinion on the use of Polyglycitol Syrup as a food additive - doi:10.2903/j.efsa.2009.1413
openFDA substances 4 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
openFDA substances FDA UNII substance identifier D65DG142WK UNII - - - chemical {"approval_status":null,"molecular_formula":"C12H24O11","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"D65DG142WK"}
openFDA substances FDA UNII substance identifier D65DG142WK UNII - - - chemical {"approval_status":null,"molecular_formula":"C12H24O11","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"D65DG142WK"}
openFDA substances FDA UNII substance identifier D65DG142WK UNII - - - chemical {"approval_status":null,"molecular_formula":"C12H24O11","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"D65DG142WK"}
openFDA substances FDA UNII substance identifier D65DG142WK UNII - - - chemical {"approval_status":null,"molecular_formula":"C12H24O11","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"D65DG142WK"}